CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleMarket cap is $2.32B, above the global median of $1.18B
- PositionReturn on equity is 17.1%, higher than 95% of its Medical Devices peers (median 2.5%)
- Interpretations7 currently firing — 7
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.32BUSDvs all stocks (USD)
Trailing P/E
31.99xvs Medical Devices peers
Revenue (TTM)
631.64MUSDvs all stocks (USD)
Profit Margin
11.45%vs Medical Devices peers
Beta
1.07xvs all stocks
52-Week Change
50.22%vs all stocks
Market Capitalization
2.32BUSDvs all stocks (USD)
Enterprise Value
2.42BUSDvs all stocks (USD)
Trailing P/E
31.99xvs Medical Devices peers
Forward P/E
24.92xvs Medical Devices peers
PEG Ratio
1.55xvs Medical Devices peers
Price to Sales (TTM)
3.63xvs Medical Devices peers
Price to Book (MRQ)
4.96xvs Medical Devices peers
Enterprise to Revenue
3.83xvs Medical Devices peers
Enterprise to EBITDA
20.86xvs Medical Devices peers
Gross Margin
29.27%vs Medical Devices peers
Profit Margin
11.45%vs Medical Devices peers
Operating Margin
16.19%vs Medical Devices peers
Return on Assets (TTM)
9.13%vs Medical Devices peers
Return on Equity (TTM)
17.05%vs Medical Devices peers
Revenue (TTM)
631.64MUSDvs all stocks (USD)
Revenue per Share (TTM)
81.80USDUpdated Sep 28, 2026Quarterly Revenue Growth
15.10%vs Medical Devices peers
Gross Profit (TTM)
180.00MUSDvs all stocks (USD)
EBITDA (TTM)
115.91MUSDvs all stocks (USD)
Net Income (TTM)
72.30MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
21.40%vs Medical Devices peers
Operating Cash Flow (TTM)
71.58MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
34.87MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Medical Devices peers
Revenue
602.80MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
432.39MUSDFY2025 · Dec 31, 2025Gross Profit
170.41MUSDFY2025 · Dec 31, 2025Operating Income
92.97MUSDvs all stocks (USD)
Pre-tax Income
82.51MUSDFY2025 · Dec 31, 2025Income Tax Expense
14.20MUSDFY2025 · Dec 31, 2025Net Income
68.31MUSDFY2025 · Dec 31, 2025EBIT
92.32MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
112.10MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
77.44MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
9.80MUSDFY2025 · Dec 31, 2025EPS (Basic)
8.87USDFY2025 · Dec 31, 2025EPS (Diluted)
8.75USDFY2025 · Dec 31, 2025Basic Shares Outstanding
7.71MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
7.71MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
68.31MUSDFY2025 · Dec 31, 2025Operating Cash Flow
96.45MUSDFY2025 · Dec 31, 2025Free Cash Flow
83.57MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
20.30MUSDFY2025 · Dec 31, 2025Income Tax Paid
2.78MUSDFY2025 · Dec 31, 2025Interest Paid
9.86MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
68.31MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
19.15MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
5.11MUSDFY2025 · Dec 31, 2025Stock-based Compensation
8.85MUSDFY2025 · Dec 31, 2025Other Non-cash Items
261.00KUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
4.79MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-1.09MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-8.94MUSDFY2025 · Dec 31, 2025Capital Expenditures
-12.88MUSDFY2025 · Dec 31, 2025Net Acquisitions
-14.72MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-27.60MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
68.70MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-122.68MUSDFY2025 · Dec 31, 2025Other Financing Charges
-4.37MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-58.35MUSDFY2025 · Dec 31, 2025Shares Outstanding
7.75MSharesUpdated Sep 28, 2026Float Shares
7.48MSharesUpdated Sep 28, 2026Shares Short
1.05MSharesUpdated Sep 28, 2026Short Ratio
8.95daysvs all stocks
Short % of Shares Outstanding
18.91%vs all stocks
% Held by Insiders
3.81%vs all stocks
% Held by Institutions
127.33%vs all stocks
Total Cash (MRQ)
9.04MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
1.17USDUpdated Sep 28, 2026Total Debt (MRQ)
136.34MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.2948xvs Medical Devices peers
Current Ratio (MRQ)
3.00xvs Medical Devices peers
Book Value per Share (MRQ)
59.70USDUpdated Sep 28, 2026Total Assets
655.08MUSDvs all stocks (USD)
Total Current Assets
201.00MUSDFY2025 · Dec 31, 2025Total Liabilities
231.20MUSDFY2025 · Dec 31, 2025Total Non-current Assets
454.08MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
156.34MUSDFY2025 · Dec 31, 2025Total Current Liabilities
74.86MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
20.30MUSDFY2025 · Dec 31, 2025Accounts Receivable
82.91MUSDFY2025 · Dec 31, 2025Inventory
86.86MUSDFY2025 · Dec 31, 2025Accounts Payable
24.29MUSDFY2025 · Dec 31, 2025Short-term Debt
17.54MUSDFY2025 · Dec 31, 2025Deferred Revenue
4.24MUSDFY2025 · Dec 31, 2025Long-term Debt
136.94MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
3.52MUSDFY2025 · Dec 31, 2025Common Stock (Book)
77.00KUSDFY2025 · Dec 31, 2025Retained Earnings
374.81MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
423.88MUSDvs all stocks (USD)
Treasury Stock
587.00KUSDFY2025 · Dec 31, 202552-Week Low
173.86USDUpdated Sep 28, 202652-Week High
338.71USDUpdated Sep 28, 202652-Week Change
50.22%vs all stocks
Beta
1.07xvs all stocks
50-Day MA
287.20USDUpdated Sep 28, 2026200-Day MA
241.69USDUpdated Sep 28, 2026Avg 10-Day Volume
102.89KSharesUpdated Sep 28, 2026Avg 30-Day Volume
112.64KSharesUpdated Sep 28, 2026Diluted EPS (TTM)
9.25USDUpdated Sep 28, 2026Other Income / Expense
-654.00KUSDFY2025 · Dec 31, 20257 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
FCF Ratios Elevated
Its free cash flow is large next to assets and equity, and more of its operating cash reaches it than in its industry.
Reads
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
Low Fixed-Asset Share With Elevated Turnover
It owns few buildings and machines, yet gets more sales and profit from its assets than its industry does.
Reads
Operating Income Growing With Multi-Year Revenue Growth
Revenue up in each of five years, with operating income up in each of four.
Reads
Multi-Year FCF With Growth And Margin
Three years of positive free cash flow and rising revenue, four of rising equity, and much of its sales turns into cash.
Reads
ROE, ROA, And Operating ROA Elevated
It earns more on its equity than its industry does, and on its assets too — not on borrowing alone.
Reads
Is this company growing?
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Return on equity is 17.1%, higher than 95% of its Medical Devices peers (median 2.5%)Significant
Return on equity: 0.17Industry median: 0.03Industry P95: 0.17Peers compared: 102
Financial Health
Altman Z-Score 8.44: safe zoneNotable
Altman Z-Score: 8.44
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Market cap is $2.32B, above the global median of $1.18BNotable
Market cap (USD): 2,320,251,394Global Median: 1,180,223,658.953
Revenue is $631.64M, above the global median of $548.88MNotable
Revenue (USD): 631,638,976Global Median: 548,883,780.48
Levered free cash flow is $34.87M, above the global median of $18.73MNotable
Levered free cash flow (USD): 34,872,376Global Median: 18,729,043.027
Companies that share the same coordination system — how they create, deliver, or capture value.
Shandong Buchang Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Tonghua Dongbao Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
GemPharmatech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Viridian Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Vera Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Sellas Life Sciences Group Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Mineralys Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
ApicHope Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
ABL Bio Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Nurix Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Polycab India Ltd.
7 interpretationsFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedOperating Income Growing With Multi-Year Revenue GrowthMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked Return on Capital ElevatedLow Fixed-Asset Share With Elevated TurnoverMulti-Year FCF With Growth And Margin
Medpace Holdings Inc.
6 interpretationsFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedOperating Income Growing With Multi-Year Revenue GrowthMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked Return on Capital ElevatedLow Fixed-Asset Share With Elevated Turnover
Trane Technologies plc
6 interpretationsFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked Return on Capital ElevatedLow Fixed-Asset Share With Elevated TurnoverMulti-Year FCF With Growth And Margin